HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Management of factor VII-deficient patients undergoing joint surgeries--preliminary results of locally developed treatment regimen.

Abstract
Inherited factor VII (FVII) deficiency is a rare coagulation disorder with variable haemorrhagic manifestations. In severely affected cases spontaneous haemarthroses leading to advanced arthropathy have been observed. Such cases may require surgery. Therapeutic options for bleeding prevention in FVII deficient patients undergoing surgery comprise various FVII preparations but the use of recombinant activated factor VII (rFVIIa) seems to be the treatment of choice. To present the outcome of orthopaedic surgery under haemostatic coverage of rFVIIa administered according to the locally established treatment regimen in five adult patients with FVII baseline plasma levels below 10 IU dL(-1). Two patients required total hip replacement (THR); three had various arthroscopic procedures. Recombinant activated factor VII was administered every 8 h on day of surgery (D0) followed by every 12-24 h for the subsequent 9-14 days, depending on the type of surgery. Factor VII plasma coagulation activity (FVII:C) was determined daily with no predefined therapeutic target levels. Doses of rFVIIa on D0 ranged from 18 to 37 μg kg(-1) b.w. and on the subsequent days--from 13 to 30 μg kg(-1) b.w. Total rFVIIa dose per procedure ranged from 16 to 37.5 mg, and the total number of doses per procedure was 16-31. None of our patients developed excessive bleeding including those in whom FVII:C trough levels returned nearly to the baseline level on the first post-op day. Preliminary results demonstrate that rFVIIa administered according to our treatment regimen is an effective and safe haemostatic agent for hypoproconvertinaemia patients undergoing orthopaedic surgery.
AuthorsJ Windyga, P Zbikowski, P Ambroziak, B Baran, I Kotela, E Stefanska-Windyga
JournalHaemophilia : the official journal of the World Federation of Hemophilia (Haemophilia) Vol. 19 Issue 1 Pg. 89-93 (Jan 2013) ISSN: 1365-2516 [Electronic] England
PMID22845882 (Publication Type: Journal Article)
Copyright© 2012 Blackwell Publishing Ltd.
Chemical References
  • Coagulants
  • Recombinant Proteins
  • recombinant FVIIa
  • Factor VIIa
Topics
  • Adult
  • Aged
  • Blood Loss, Surgical (prevention & control)
  • Coagulants (therapeutic use)
  • Factor VII Deficiency (complications, drug therapy, surgery)
  • Factor VIIa (therapeutic use)
  • Female
  • Hemostasis, Surgical (methods)
  • Humans
  • Male
  • Middle Aged
  • Orthopedics (methods)
  • Postoperative Hemorrhage (prevention & control)
  • Recombinant Proteins (therapeutic use)
  • Surgical Procedures, Operative (methods)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: